Description of Medical ServiceCell-free fetal DNA (cffDNA) present in the maternal circulation is detected by high-throughput non-invasive prenatal testing (HT-NIPT), using real-time quantitative polymerase chain reaction (PCR). HT-NIPT is used to determine the RhD genotype of a fetus carried by a RhD-negative woman by detecting the presence of cffDNA fragments in the mother’s plasma. The presence of RhD-positive cffDNA would indicate the presence of a RHD gene, which suggests a RhD-positive fetus.
Description of Medical ConditionApproximately one in seven women has a rhesus (Rh) D-negative blood group. RhD negative women carrying an RhD-positive fetus are at risk of becoming sensitised, producing antibodies against the RhD antigen if fetal cells enter the maternal circulation. Sensitisation places the RhD-positive fetus and future RhD-positive pregnancies at risk of haemolytic disease of the fetus and newborn (HDFN). If undiagnosed and/or untreated, HDFN carries significant risk of perinatal morbidity and mortality.1 In Australia, the current standard of care is the routine administration anti-D immunoglobulin to all RhD negative pregnant women at 28 and 34 weeks’ gestation, and within 72 hours of delivery of an RhD-positive fetus, or following other obstetric events associated with a risk of fetal-to-maternal haemorrhage.
Reason for ApplicationNew MBS item(s)
Medical Service TypeInvestigative
Previous Application NumberNot Applicable
Application FormApplication Form (PDF 1583 KB)
Application Form (Word 400 KB)
Consultation SurveyConsultation Survey (PDF 487 KB)
Consultation Survey (Word 71 KB)
PICO ConfirmationPICO Confirmation (PDF 1240 KB)
PICO Confirmation (Word 438 KB)
Public Summary DocumentPublic Summary Document (PDF 637 KB)
Public Summary Document (Word 326 KB)